CVS HEALTH Corp Form 10-Q November 04, 2014

UNITED STATES			
SECURITIES AND EXCHANGE COMMISSION			
Washington, D.C. 20549			
FORM 10-Q			
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE 1934 For the Quarterly Period Ended September 30, 2014	SECURITIES EXCHANGE ACT OF		
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE 1934  For the transition period from to	SECURITIES EXCHANGE ACT OF		
Commission File Number 001-01011			
CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter)			
Delaware (State of Incorporation)	05-0494040 (I.R.S. Employer Identification Number)		
One CVS Drive, Woonsocket, Rhode Island 02895 (Address of principal executive offices)			
Registrant's telephone number, including area code: (401) 765-1500			
Indicate by check mark whether the registrant (1) has filed all reports required Securities Exchange Act of 1934 during the preceding 12 months (or for such sequired to file such reports), and (2) has been subject to such filing requirements.	shorter period that the registrant was		
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]			
Indicate by check mark whether the registrant is a large accelerated filer, an ac a smaller reporting company. See the definitions of "large accelerated filer," "company" in Rule 12b-2 of the Exchange Act.			
Large accelerated filer [X]  Non-accelerated filer [ ] (Do not check if a smaller reporting company)	Accelerated filer [ ] Smaller reporting company [ ]		

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  $[\ ]$  No [X]

Common Stock, \$0.01 par value, issued and outstanding at October 30, 2014:

1,146,383,477 shares

### **INDEX**

Part I		Page
Item 1.	Financial Statements	
	Condensed Consolidated Statements of Income (Unaudited) - Three and Nine Months Ended September 30, 2014 and 2013	<u>3</u>
	Condensed Consolidated Statements of Comprehensive Income (Unaudited) - Three and Nine Months Ended September 30, 2014 and 2013	4
	Condensed Consolidated Balance Sheets (Unaudited) - As of September 30, 2014 and December 31, 2013	<u>5</u>
	Condensed Consolidated Statements of Cash Flows (Unaudited) - Nine Months Ended September 30, 2014 and 2013	<u>6</u>
	Notes to Condensed Consolidated Financial Statements (Unaudited)	7
	Report of Independent Registered Public Accounting Firm	<u>19</u>
Item 2. Item 3. Item 4.	Management's Discussion and Analysis of Financial Condition and Results of Operations Quantitative and Qualitative Disclosures About Market Risk Controls and Procedures	20 34 34
<u>Part II</u>		
Item 1.	<u>Legal Proceedings</u>	<u>36</u>
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	<u>37</u>
Item 6.	<u>Exhibits</u>	<u>38</u>
<u>Signatures</u>		<u>39</u>

Part I Item 1

CVS Health Corporation (formerly CVS Caremark Corporation) Condensed Consolidated Statements of Income (Unaudited)

	Three Months Ended September 30,		Nine Months September 30		
In millions, except per share amounts	2014	2013	2014	2013	
Net revenues	\$35,021	\$31,932	\$102,312	\$93,931	
Cost of revenues	28,553	25,905	83,578	76,487	
Gross profit	6,468	6,027	18,734	17,444	
Operating expenses	4,222	3,873	12,256	11,624	
Operating profit	2,246	2,154	6,478	5,820	
Interest expense, net	153	122	469	374	
Loss on early extinguishment of debt	521		521		
Income before income tax provision	1,572	2,032	5,488	5,446	
Income tax provision	624	777	2,165	2,112	
Income from continuing operations	948	1,255	3,323	3,334	
Loss from discontinued operations, net of tax		(6)		(7	)
Net income	\$948	\$1,249	\$3,323	\$3,327	
Basic earnings per share:					
Income from continuing operations	\$0.82	\$1.03	\$2.84	\$2.72	
Loss from discontinued operations	<b>\$</b> —	<b>\$</b> —	<b>\$</b> —	\$(0.01	)
Net income	\$0.82	\$1.03	\$2.84	\$2.71	
Weighted average basic shares outstanding	1,157	1,218	1,167	1,226	
Diluted earnings per share:					
Income from continuing operations	\$0.81	\$1.02	\$2.82	\$2.70	
Loss from discontinued operations	<b>\$</b> —	\$—	\$—	\$(0.01	)
Net income	\$0.81	\$1.02	\$2.82	\$2.70	
Weighted average diluted shares outstanding	1,164	1,226	1,175	1,234	
Dividends declared per share	\$0.275	\$0.225	\$0.825	\$0.675	

See accompanying notes to condensed consolidated financial statements.

3

CVS Health Corporation (formerly CVS Caremark Corporation) Condensed Consolidated Statements of Comprehensive Income (Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,		
In millions	2014	2013	2014	2013	
Net income	\$948	\$1,249	\$3,323	\$3,327	
Other comprehensive income (loss):					
Foreign currency translation adjustments, net of tax	(29	) 3	(14	) (15	
Cash flow hedges, net of tax	1	1	3	2	
Total other comprehensive income (loss)	(28	) 4	(11	) (13	
Comprehensive income	\$920	\$1,253	\$3,312	\$3,314	

See accompanying notes to condensed consolidated financial statements.

4

#### CVS Health Corporation (formerly CVS Caremark Corporation) Condensed Consolidated Balance Sheets (Unaudited)

In millions, except per share amounts	September 30, 2014	December 31, 2013
Assets:		
Cash and cash equivalents	\$1,132	\$4,089
Short-term investments	78	88
Accounts receivable, net	10,828	8,729
Inventories	11,613	11,045
Deferred income taxes	1,042	902
Other current assets	644	472
Total current assets	25,337	25,325
Property and equipment, net	8,694	8,615
Goodwill	28,151	26,542
Intangible assets, net	9,854	9,529
Other assets	1,540	1,515
Total assets	\$73,576	\$71,526
***		
Liabilities:	Φ.C. 022	Φ.Σ. Σ.4.0
Accounts payable	\$6,033	\$5,548
Claims and discounts payable	5,400	4,548
Accrued expenses	5,433	4,768
Short-term debt	775	
Current portion of long-term debt	572	561
Total current liabilities	18,213	15,425
Long-term debt	11,709	12,841
Deferred income taxes	4,051	3,901
Other long-term liabilities	1,494	1,421
Commitments and contingencies (Note 12)	_	_
Shareholders' equity:		
CVS Health shareholders' equity:		
Preferred stock, par value \$0.01: 0.1 share authorized; none issued or outstanding		
Common stock, par value \$0.01: 3,200 shares authorized; 1,690 shares issued and		
1,153		
shares outstanding at September 30, 2014 and 1,680 shares issued and 1,180 shares		4-
outstanding at December 31, 2013	17	17
Treasury stock, at cost: 536 shares at September 30, 2014 and 500 shares at		
December 31,		
2013	(22,877 )	(,)
Shares held in trust: 1 share at September 30, 2014 and December 31, 2013	(31)	(-
Capital surplus	30,310	29,777
Retained earnings	30,845	28,493
Accumulated other comprehensive income (loss)		(149)
Total CVS Health shareholders' equity	38,104	37,938

Noncontrolling interest	5	
Total shareholders' equity	38,109	37,938
Total liabilities and shareholders' equity	\$73,576	\$71,526

See accompanying notes to condensed consolidated financial statements.

5

#### CVS Health Corporation (formerly CVS Caremark Corporation) Condensed Consolidated Statements of Cash Flows (Unaudited)

In millions Cash flows from operating activities:	Nine Mo Septemb 2014		hs Ended 30, 2013	
Cash receipts from customers	\$95,816		\$85,408	;
Cash paid for inventory and prescriptions dispensed by retail network pharmacies			(67,826	
Cash paid to other suppliers and employees	(11,267	)	(10,760	)
Interest received	11		5	
Interest paid	(458	)	(369	)
Income taxes paid	(2,321	)	(2,213	)
Net cash provided by operating activities	4,714		4,245	
Cash flows from investing activities:				
Purchases of property and equipment	(1,436	)	(1,330	)
Proceeds from sale-leaseback transactions	328		156	
Proceeds from sale of property and equipment	8		13	
Acquisitions (net of cash acquired) and other investments	(2,392	-	(354	)
Purchase of available-for-sale investments	(161	)	(107	)
Sales/maturities of available-for-sale investments	119			
Net cash used in investing activities	(3,534	)	(1,622	)
Cash flows from financing activities:				
Increase in short-term debt	775		124	
Proceeds from issuance of long-term debt	1,483		_	
Repayments of long-term debt	(3,086			
Dividends paid	(971	)	(829	)
Proceeds from exercise of stock options	378		431	
Excess tax benefits from stock-based compensation	89		48	
Repurchase of common stock	(2,801	-	(2,272)	)
Net cash used in financing activities	(4,133		(2,498	)
Effect of exchange rate changes on cash and cash equivalents	(4		5	
Net increase (decrease) in cash and cash equivalents	(2,957	)	130	
Cash and cash equivalents at beginning of period	4,089		1,375	
Cash and cash equivalents at end of period	\$1,132		\$1,505	
Reconciliation of net income to net cash provided by operating activities:				
Net income	\$3,323		\$3,327	
Adjustments to reconcile net income to net cash provided by operating activities:				
Depreciation and amortization	1,442		1,412	
Stock-based compensation	121		101	
Loss on early extinguishment of debt	521			
Deferred income taxes and other noncash items	(64	)	129	
Change in operating assets and liabilities, net of effects from acquisitions:				
Accounts receivable, net	(1,872	-	(1,518	)
Inventories	(449	)	(79	)

Other current assets	(160 ) 176
Other assets	(19 ) (125 )
Accounts payable and claims and discounts payable	1,222 697
Accrued expenses	676 76
Other long-term liabilities	(27 ) 49
Net cash provided by operating activities	\$4,714